Cargando…

Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study

Significant anti-spike protein receptor-binding domain (S-RBD) antibody responses have been demonstrated in patients with chronic disorder of consciousness (DOC) completing a COVID-19 vaccine regime with BNT162b2 (Pfizer–BioNTech). We now provide further prospective data on the immunogenicity of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Pugliese, Maria Elena, Battaglia, Riccardo, Raso, Maria Girolama, Chiaravalloti, Raffaela, Coschignano, Francesco, Pagliuso, Angela, Bruschetta, Roberta, Pugliese, Giovanni, Scola, Paolo, Tonin, Paolo, Cerasa, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149894/
https://www.ncbi.nlm.nih.gov/pubmed/35645314
http://dx.doi.org/10.3390/clinpract12030037
_version_ 1784717302904651776
author Pugliese, Maria Elena
Battaglia, Riccardo
Raso, Maria Girolama
Chiaravalloti, Raffaela
Coschignano, Francesco
Pagliuso, Angela
Bruschetta, Roberta
Pugliese, Giovanni
Scola, Paolo
Tonin, Paolo
Cerasa, Antonio
author_facet Pugliese, Maria Elena
Battaglia, Riccardo
Raso, Maria Girolama
Chiaravalloti, Raffaela
Coschignano, Francesco
Pagliuso, Angela
Bruschetta, Roberta
Pugliese, Giovanni
Scola, Paolo
Tonin, Paolo
Cerasa, Antonio
author_sort Pugliese, Maria Elena
collection PubMed
description Significant anti-spike protein receptor-binding domain (S-RBD) antibody responses have been demonstrated in patients with chronic disorder of consciousness (DOC) completing a COVID-19 vaccine regime with BNT162b2 (Pfizer–BioNTech). We now provide further prospective data on the immunogenicity of these patients followed by heterologous booster injection with mRNA-1273 (Moderna). These patients were compared with two different demographically comparable healthcare workers (HCW) groups who underwent homologous booster injection with BNT162b2 vaccine or heterologous booster injection with mRNA-1273. Antibody responses were evaluated at 21 days after the administration of the booster dose of vaccination. Results: No severe adverse reactions were reported after each type of vaccination. Heterologous boosting with mRNA-1273 elicited a higher increase of S-RBD IgG levels than homologous boosting with BNT162b2 both in DOC patients and HCW who had previously received two doses of BNT162b2. No significant difference was detected between DOC and HCW patients who received heterologous boosting. Conclusions: Despite the small sample size, our preliminary results suggest that heterologous boosting with mRNA-1273, following initial vaccination with BNT162b2, is safe and tends to be more immunogenic than homologous boosting, either in fragile people or in healthy controls.
format Online
Article
Text
id pubmed-9149894
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91498942022-05-31 Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study Pugliese, Maria Elena Battaglia, Riccardo Raso, Maria Girolama Chiaravalloti, Raffaela Coschignano, Francesco Pagliuso, Angela Bruschetta, Roberta Pugliese, Giovanni Scola, Paolo Tonin, Paolo Cerasa, Antonio Clin Pract Communication Significant anti-spike protein receptor-binding domain (S-RBD) antibody responses have been demonstrated in patients with chronic disorder of consciousness (DOC) completing a COVID-19 vaccine regime with BNT162b2 (Pfizer–BioNTech). We now provide further prospective data on the immunogenicity of these patients followed by heterologous booster injection with mRNA-1273 (Moderna). These patients were compared with two different demographically comparable healthcare workers (HCW) groups who underwent homologous booster injection with BNT162b2 vaccine or heterologous booster injection with mRNA-1273. Antibody responses were evaluated at 21 days after the administration of the booster dose of vaccination. Results: No severe adverse reactions were reported after each type of vaccination. Heterologous boosting with mRNA-1273 elicited a higher increase of S-RBD IgG levels than homologous boosting with BNT162b2 both in DOC patients and HCW who had previously received two doses of BNT162b2. No significant difference was detected between DOC and HCW patients who received heterologous boosting. Conclusions: Despite the small sample size, our preliminary results suggest that heterologous boosting with mRNA-1273, following initial vaccination with BNT162b2, is safe and tends to be more immunogenic than homologous boosting, either in fragile people or in healthy controls. MDPI 2022-05-11 /pmc/articles/PMC9149894/ /pubmed/35645314 http://dx.doi.org/10.3390/clinpract12030037 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Pugliese, Maria Elena
Battaglia, Riccardo
Raso, Maria Girolama
Chiaravalloti, Raffaela
Coschignano, Francesco
Pagliuso, Angela
Bruschetta, Roberta
Pugliese, Giovanni
Scola, Paolo
Tonin, Paolo
Cerasa, Antonio
Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study
title Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study
title_full Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study
title_fullStr Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study
title_full_unstemmed Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study
title_short Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study
title_sort heterologous covid-19 booster vaccination in the chronic disorder of consciousness: a pilot study
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149894/
https://www.ncbi.nlm.nih.gov/pubmed/35645314
http://dx.doi.org/10.3390/clinpract12030037
work_keys_str_mv AT pugliesemariaelena heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy
AT battagliariccardo heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy
AT rasomariagirolama heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy
AT chiaravallotiraffaela heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy
AT coschignanofrancesco heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy
AT pagliusoangela heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy
AT bruschettaroberta heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy
AT pugliesegiovanni heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy
AT scolapaolo heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy
AT toninpaolo heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy
AT cerasaantonio heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy